FAQs about co-financing

in page functions

Frequently asked questions about Gavi's revised co-financing, prepared by the Gavi Secretariat in June 2012.

What is co-financing?

Co-financing is a term used by Gavi to signify that countries share a portion of the cost of their new vaccines and safe injection devices. Co-financing is actually co-procurement of Gavi-supported vaccines and safe injection devices by countries.

Countries are asked to start co-financing as soon as they introduce new Gavi-supported vaccines and, depending on their level of GNI per capita, to make gradually increasing contributions. The objective is to put countries on a trajectory towards financial sustainability in order to prepare them for phasing out of Gavi support for new vaccines.

The timeframe for attaining financial sustainability will vary across countries. For the poorest countries, many years may be required to achieve financial sustainability, and therefore an intermediate objective is to gradually enhance country contribution and ownership of vaccine financing. The vaccines exempt from co-financing are measles second dose and preventive campaigns with measles-rubella, Meningococcal A and Yellow Fever vaccines.


Over the course of a decade, the weighted average price of pentavalent vaccine (DTP-hepB-Hib) dropped by 43% from US$ 3.56 per dose in 2003 to US$ 2.04 per dose in 2013, with a lowest-ever price of US$ 1.19 from one supplier in 2013.


More facts...

close icon

modal window here